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Abstract. Standard lymphadenectomy for prostate cancer 
is limited to the obturator lymph nodes (LNs), although the 
internal and external iliac LNs represent the primary landing 
zone for prostatic lymphatic drainage. We performed anatomi-
cally semi-extended pelvic lymph node dissection (PLND) to 
assess the incidence of LN metastasis in cases of clinically 
localized prostate cancer. A total of 730 consecutive patients 
underwent radical prostatectomy with either semi-extended 
PLND, comprising 6 selective fields, namely the external 
iliac, internal iliac and obturator LNs bilaterally, or standard 
LND (obturator LNs alone). A total of 131 patients under-
going semi-extended PLND were compared with 599 patients 
undergoing standard LND. The patients were stratified into 
high-risk [prostate‑specific antigen (PSA)>20 ng̸ml, Gleason 
score (GS)≥8], intermediate-risk (PSA 10-20 ng̸ml, GS=4+3) 
and low-risk (PSA<10 ng̸ml, GS≤3+4) subgroups. Following 
semi-extended LND, positive LNs were detected in 12/61 (20%) 
of the high-risk, 1/30 (3%) of the intermediate-risk and 0/40 (0%) 
of the low-risk cases. Following standard LND, positive LNs 
were detected in 13/182 (7%) of the high-risk, 1/164 (0.6%) of 
the intermediate-risk and 0/253 (0%) of the low-risk cases. In 
high-risk patients, the detection rate of LN metastasis was signifi-
cantly higher following extended LND compared with standard 
LND (P<0.01). In 9 of 13 patients (69%), metastases were identi-
fied in the internal and external iliac regions, despite negative 
obturator LNs. There were no significant differences regarding 
intraoperative and postoperative complications or blood loss in 
the two groups. There was no lymphocele formation in patients 
undergoing either standard or semi-extended LND. Extended 
pelvic LND (PLND) is associated with a high rate of LN metas-
tasis detection outside the fields of standard LND in cases with 
clinically localized prostate cancer. Therefore, LND including 
the internal and external iliac LNs should be performed in all 
patients with high-risk prostate cancer; however, in the low-risk 
group, PLND may be omitted.
Introduction
Pelvic lymph node dissection (PLND) at the time of radical 
prostatectomy (RP) is currently the most reliable method for 
detecting lymph node (LN) metastases in patients with pros-
tate cancer (1-4). Conventionally, only the obturator LNs are 
included in LND for prostate cancer; such a narrow dissection 
range may be associated with the low number of node-positive 
cases. Indeed, Miyake et al (5) demonstrated that localized 
LND in RP was insufficient. Extended LND (ELND) has been 
recommended, as it increases the node-positive rate in localized 
prostate cancer. However, an increased risk of complications 
associated with ELND has also been reported (6,7).
To verify whether the node-positive rate is increased by 
widening the dissection range and whether ELND may be 
safely performed on a routine basis, we conducted a compara-
tive study between a group of patients treated with the ELND 
proposed by Bader et al (8), where the obturator foramen LNs 
were excised along with the internal and external iliac LNs, 
and another group treated with conventional obturator LND 
alone.
Standard LND for prostate cancer is limited to obturator 
LNs, although the internal and external LNs represent the 
primary landing zone for prostatic lymphatic drainage. 
Heidenreich et al (9) reported that, considering their data, 
dissection of the presacral and common iliac lymphatics 
does not appear to be necessary, since only 3 of 95 patients 
(3.1%) had LN metastasis in that region. Heidenreich et al (9) 
and Zincke (10) have also demonstrated the high diagnostic 
accuracy of pelvic staging LND limited to the internal and 
external iliac and the obturator fossa LNs. We referred to LND 
limited to the internal and external iliac and obturator fossa 
LNs as ‘semi-extended’ LND and compared it to standard 
LND (obturator fossa LNs alone).
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An anatomically semi-extended PLND and a conventional 
limited PLND were performed, in order to assess the inci-
dence of LN metastasis in cases of clinically localized prostate 
cancer and evaluate the cases with metastases to the LNs.
Patients and methods
Patient stratification by treatment. We retrospectively queried 
our database for patients who underwent open RP between 1988 
and 2013 in Yamagata Prefectural Central Hospital  (Yamagata, 
Japan). Ethics approval was obtained from the Institutional 
Review Board of the Yamagata Prefectural Central Hospital 
(approval no. 2013-0003). Patients who received neoadjuvant or 
immediate adjuvant therapy were included in the study. A total 
of 730 consecutive patients underwent RP. The patients were 
divided into two groups, the group undergoing semi-extended 
PLND, comprising 6 selective fields, namely the bilateral 
external iliac, internal iliac and obturator fields, and the group 
undergoing standard LND (obturator LNs alone).
Patient stratification by risk. A total of 131 patients who 
underwent semi-extended PLND were compared with 
599 standard LND patients (Table I). The patients were strati-
fied into high-risk [prostate‑specific antigen (PSA)>20 ng̸ml, 
Gleason score (GS)≥8], intermediate-risk (PSA 10‑20 ng̸ml, 
GS=4+3) and low-risk (PSA<10 ng̸ml, GS≤3+4) subgroups. 
The patients were followed up for a median of 40 months 
(range, 1-261 months).
Results
Positive LN detection by treatment and risk group. Following 
semi-extended LND, positive LNs were detected in 
12/61 (20%) of the high-risk, 1/30 (3%) of the intermediate-risk 
and 0/40 (0%) of the low-risk cases. Standard LND identified 
positive LNs in 13/182 (7%) of the high-risk, 1/164 (0.6%) of 
the intermediate-risk and 0/253 (0%) of the low-risk cases. In 
the high-risk group, the detection rate of LN metastasis was 
significantly higher following extended LND compared with 
that following standard LND (Table I, P<0.01).
In 9 of 13 patients (69%), metastases were identified in the 
internal and external iliac regions, despite negative obturator 
LNs. The range, mean and median number of harvested LNs 
were 0-24, 6.7 and 6, respectively, with standard LND and 0-34, 
10.8 and 9, respectively, with semi-extended LND (P<0.01). 
The PSA of patients with LN metastasis ranged between 
3.3 and 252.7 ng̸ml (mean, 49.7 and median, 38 ng̸ml). All 
the patients with a single obturator LN metastasis underwent 
standard LND.
In the 2 intermediate-risk patients exhibiting LN metas-
tasis, the serum PSA level (GS) was 6.7 ng/ml (4+3) and 
16.1 ng/ml (4+3), respectively.
Complications and outcome. There were no significant 
differences regarding intraoperative and postoperative compli-
cations or blood loss between the two groups. There was no 
lymphocele formation in patients undergoing either standard 
or semi-extended LND. The Kaplan-Meier curves for the 
oncological outcomes of progression-free survival (PFS) and 
cause‑specific survival (CSS) are shown in Fig. 1.
Discussion
LND in RP is considered to be of diagnostic value; however, 
its curative significance is limited. The detection rate of LN 
metastasis may be increased by widening the dissection range, 
although the extent of the dissection remains controversial. 
Clark et al (11) performed a prospective comparative study on 
extended and localized LND and observed no difference in the 
node-positive rate; in addition, ELND was associated with a 
higher complication rate. Kroepfl et al (12) included obturator 
and internal iliac LNs, as well as the LNs along the hypogastric 
vein, in the range of ELND. Heidenreich et al (9) suggested 
it was unnecessary to dissect the presacral and common iliac 
lymphatics, since only 3 of their 95 patients (3.1%) had LN 
metastasis in that region. Heidenreich et al (9) and Zincke (10) 
demonstrated the high diagnostic accuracy of staging PLND 
limited to the internal and external iliac and obturator fossa 
LNs. An autopsy study by Weingärtner et al (13) suggested that 
20 LNs must be retrieved for an adequate PLND. In the present 
study, the cancer‑specific 5‑year survival rate of pN1 patients 
was 89%, which supports the curative significance of LND.
Retrospective analyses demonstrated that the number 
of positive LNs may affect survival. Certain studies have 
suggested that RP may be curative for a proportion of patients 
with LN-positive prostate cancer. Sterinberg et al (14) followed 
64 patients with positive nodes, of whom 83 and 68% remained 
free of detectable tumor at 60 and 80 months following RP, 
Table I. Number of positive lymph nodes (LNs) stratified by 
risk group and extent of LN dissection (LND).
 LND type
 ------------------------------------------------------------------
Risk Standard Semi-extended
Low (%) 0/253 (0.0) 0/40 (0.0)
Intermediate (%) 1/164 (0.6) 1/30 (3.3)
Higha (%) 13/182 (7.1) 12/61 (19.6)b
aLN positivity rate in high-risk patients: standard vs. semi-extended 
LND; Fisher's exact test, P<0.05; Chi-square, 7.771. bLN positivity 
rate in semi-extended LND: high-risk vs. intermediate-/low-risk 
patients; Fisher's exact test, P<0.001; Chi-square, 10.181.
Figure 1. Kaplan-Meier curves for oncological outcomes, namely progres-
sion‑free survival (PFS) and cause‑specific survival (CSS) of N1 cases.
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respectively, and identified the tumor burden of the diseased 
LNs as an independent prognostic factor.
Our data suggest a delay in disease progression for prostate 
cancer patients with minimal LN involvement when radical 
surgery is performed. The follow-up duration is insufficient 
to reach a definitive decision in terms of possible cura-
tive effect. However, depending on the tumor burden or the 
number of diseased LNs, radical surgical treatment appears to 
improve the outcome in a not precisely defined but significant 
percentage of patients. Thus, meticulous pelvic LND to remove 
all diseased nodes and ensure accurate staging, combined with 
RP, is recommended for clinically organ‑confined prostate 
cancer. The promising survival rate of patients with minimal 
nodal disease makes the value of routine immediate androgen 
ablation in all patients with positive LNs at least questionable, 
particularly when considering the side effects of hormone 
therapy.
In conclusion, semi-extended PLND was associated with a 
high rate of LN metastasis detection outside the fields of stan-
dard LND in patients with clinically localized prostate cancer. 
LND including the internal and external iliac LNs should 
be performed in all patients with high risk-prostate cancer. 
However, in the low-risk group, PLND may be omitted.
The results of the present study demonstrated that 
semi-extended PLND, as performed in our institution, 
was associated with greater nodal yields and may result in 
improved oncological outcomes in patients with LN-positive 
prostate cancer. Although a prospective trial is required to 
confirm our results, we currently recommend considering 
semi-extended LND at the time of RP for high-risk prostate 
cancer patients, whereas, in the low-risk group, PLND may be 
omitted.
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